Landmark studies such as LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide) have shown significant reductions in major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors
Most patient will use Semaglutide for 6 months to at least one year, depending on their goals
Tau pathology in neurodegenerative disease: Disease mechanisms and therapeutic avenues
Injection site rotation Rotate injection sites with each weekly dose
Responsible modeling requires naming what is not known and what warning signs exist
606 Rapamycin also reduces the loss of dopamine neurons in the substantia nigra by regulating ferritinophagy and ferroptosis